Where Will Vertex Pharmaceuticals Be in 10 Years?

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since gained the regulatory nod for four more and become the global leader in the CF market. The company also showed its strengths beyond this specialty area, collecting approvals for a gene-editing therapy for blood disorders a little over a year ago and a pain treatment just recently.Vertex's portfolio of CF drugs has fueled earnings performance over the past decade, helping the company grow product revenue to more than $11 billion in the 2024 full year. It's likely these CF drugs will continue to act as the company's main growth driver in the near term. But it's logical to ask: What's Vertex's long-term story? Where will the company be in 10 years, for example? Let's find out.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool